120 related articles for article (PubMed ID: 3412741)
1. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
[TBL] [Abstract][Full Text] [Related]
2. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Roila F; Tonato M; Basurto C; Minotti V; Ballatori E; del Favero A
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
[TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
[TBL] [Abstract][Full Text] [Related]
4. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
[TBL] [Abstract][Full Text] [Related]
5. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research.
Basurto C; Roila F; Tonato M; Ballatori E; Buzzi F; Calabresi F; Del Favero A
Am J Clin Oncol; 1989 Jun; 12(3):235-8. PubMed ID: 2729180
[TBL] [Abstract][Full Text] [Related]
8. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
9. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
[TBL] [Abstract][Full Text] [Related]
12. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
13. A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.
Basurto C; Roila F; Bracarda S; Tonato M; Ballatori E; Del Favero A
Am J Clin Oncol; 1988 Oct; 11(5):594-6. PubMed ID: 3177262
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
Roila F; Tonato M; Basurto C; Bella M; Passalacqua R; Morsia D; DiCostanzo F; Donati D; Ballatori E; Tognoni G
J Clin Oncol; 1987 Jan; 5(1):141-9. PubMed ID: 3543234
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.
David M; Durand M; Chauvergne J; Mauriac L; Bui BN; Hoerni B
Cancer Treat Rep; 1984 Jun; 68(6):921-2. PubMed ID: 6547368
[No Abstract] [Full Text] [Related]
17. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
18. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Diaz-Rubio E; Martin M; Rosell R; Valerdi JJ; Gonzalez-Larriba JL; Barriga JJ
Acta Oncol; 1991; 30(3):339-42. PubMed ID: 2036244
[TBL] [Abstract][Full Text] [Related]
19. Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
Hansen O; Pfeiffer P; Madsen B; Andersen I; Hansen B; Mathiesen B
Acta Oncol; 1996; 35(1):57-61. PubMed ID: 8619941
[TBL] [Abstract][Full Text] [Related]
20. [Antiemetic treatments associated with antineoplastic chemotherapy].
Tres Sánchez A; Sáez Martínez MJ; Mayordomo Cámara JJ; Guillén Lloveria G; Sáenz Cusi A
An Med Interna; 1990 May; 7(5):229-32. PubMed ID: 2102716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
